Abbott Laboratories (ABT) Short term Debt (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Short term Debt data on file, last reported at $4.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 771.34% year-over-year to $4.4 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (up 771.34% YoY), and the FY2025 full-year result was $3.0 billion, up 102.2% from the prior year.
• Short term Debt advanced to $4.4 billion in Q1 2026, from $3.0 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.4 billion in Q1 2026 to a low of $4.0 million in Q1 2022.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2024 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt slumped 99.47% in 2022 and jumped 57025.0% in 2023, its largest moves.
• Tracing ABT's Short term Debt over 5 years: stood at $2.3 billion in 2022, then plunged by 52.02% to $1.1 billion in 2023, then surged by 38.89% to $1.5 billion in 2024, then jumped by 102.2% to $3.0 billion in 2025, then soared by 45.37% to $4.4 billion in 2026.
• Business Quant data shows ABT's Short term Debt at $4.4 billion in Q1 2026, $3.0 billion in Q4 2025, and $1.3 billion in Q3 2025.